Sequence of Radiation and Targeted Therapy in Brain Metastases
Completed
- Conditions
- The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases
- Registration Number
- NCT04832672
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Brief Summary
The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases, including an assessment of its feasibility and toxicity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 570
Inclusion Criteria
- Had histologically proven primary cancer.
- Had newly diagnosed brain metastases in contrast-enhanced MRI.
- Brain metastases focus should be measurable.
- All the patients should safely receive radiotherapy and/or systematic tyrosine kinase inhibitors.
- Karnofsky performance score (KPS) ≥60 or KPS ≥40, but only caused by brain metastases.
Exclusion Criteria
- Patients with prior intracranial local treatments, such as surgery and radiotherapy without dose prescription in detail
- Patients with leptomeningeal metastases at first diagnosis.
- Had synchronous or metachronous malignancies that might affect survival.
- Had severe systemic diseases, abnormal conditions that might lead to incoordinate behavior during the implementation of clinical measures.
- Had incomplete sociodemographic and/or clinicopathologic baseline data
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intracranial progression-free survival The interval from the start of initial intracranial treatment to first documented intracranial progression, or date of death from any cause, whichever came first, assessed up to 3 to 5 years The survival time of patients before any intracranial progression
- Secondary Outcome Measures
Name Time Method Brain metastasis-specific survival The interval from the start of initial intracranial treatment to death from brain metastases or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years The survival time of patients dead from brain metastases
Overall survival The time from the date of initial intracranial treatment until death from any cause or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years The survival time of patients
Trial Locations
- Locations (1)
Chinese Academy of Medical Sciences
🇨🇳Beijing, Beijing, China